investiment.io
Peak Bio, Inc.
$0.07
0.05 (204.35%)
Peak Bio, Inc.
$0.07
0.05 (204.35%)
PKBO Price Chart
| Basic | |
|---|---|
| Market Cap | $4.16M |
| Price | $0.07 |
| 52 Week Range | 0.002-0.265 |
| Beta | 0.22 |
| Margins | |
| Gross Profit Margin | 99.99% |
| Operating Profit Margin | -1913.08% |
| Net Profit Margin | -1307.10% |
| Valuation (TTM) | |
| P/E Ratio | -0.35 |
| Price to Sales Ratio | 4.57 |
| Price to Book Ratio | -0.07 |
| PEG Ratio | -0.01 |
Industry
Biotechnology
Sector
Healthcare
Full-Time Employees
6
Website
IPO Date
2021-03-15T00:00:00.000Z
Description
Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics addressing unmet needs in the areas of oncology and inflammation. The company's proprietary toxin, PH-1 or Thailanstatin, a spliceosome modulator is being used to generate its first pipeline of novel ADC product candidates to address unmet needs in cancer patients. Its lead product candidate, PHP-303, is a small molecule awaiting Phase II dose clinical study in the orphan disease Alpha1 anti-trypsin deficiency (AATD). The company is based in Palo Alto, California.
Phone
650-549-9103
Address
3350 W Bayshore Rd., Palo Alto, CA, 94303, US
CIK
0001834645